含铂两药方案治疗老年晚期非小细胞肺癌的临床分析

Clinical analysis on platinum-based chemotherapy in elderly patients with advanced non-small cell lung cancer

目的探讨含铂两药方案治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法回顾性分析2008年7月至2010年12月收治的54例老年Ⅲ期非小细胞肺癌患者的临床资料,随机分为两组,每组27例,A组采用卡铂联合多西紫杉醇治疗,B组采用卡铂联合吉西他滨治疗。结果 B组患者治疗后总有效率为59.3%(16/27),与A组总有效率29.6%(8/27)比较,差异有统计学意义(P<0.05),且B组患者的1年生存率(48.2%)比A组的1年生存率(22.2%)高,组间差异有统计学意义(P<0.05),但2年生存率差异无统计学意义。另外,含铂两药方案的不良反应均表现在脊髓抑制方面。结论铂类联合细胞毒剂的两药方案一线治疗老年Ⅲ期非小细胞肺癌疗效较好,但应控制好剂量以减轻患者的不良反应。

Objective To explore the clinical effects and adverse reactions of two platinum-based chemotherapies in elderly patients with advanced non-small cell lung cancer（NSCLC）.Methods To analyze the clinical data from the 54 cases of elderly patients with advanced non-small-cell lung cancer from July 2008 to December 2010 Retrospectively.They are randomly divided into two groups,group A treated with carboplatin and docetaxel,group B with carboplatin and gemcitabine.Results There is a significant difference（P 0.05） between the overall response rate of group B（59.3%） in contrast with that of group A（29.6%）.The 1 year survival rate of group B was 48.2%,which was higher that of group A（22.2%）, the difference was statistically significant（P 0.05）,but the 2 years＇s survival rate there is no statistical significance.Side effects of both platinum-based chemotherapy are shown in the inhibition of the spinal cord.Conclusions Platinum-based chemotherapies jointed with cell toxins has a good curative effect to NSCLC,but the dose should be controlled in order to reduce the adverse reactions.